Priska™ Aims to Advance Pain Management with Suite of Online Tools in Light of Nevada Requirement to Assess Pain Risk in 2018
December 13 2017 - 2:04PM
Business Wire
Millions of Americans suffer from opioid addiction, while
millions more suffer from chronic debilitating pain. Doctors often
work to decipher the difference with limited insight into patients’
psychological conditions. Priska™ is a best-in-class online
assessments platform developed by renowned pain specialist and
psychologist Dr. Michael Lewandowski. Priska provides practitioners
with data for understanding the experience and mental health of
patients, helping to ensure they administer the best possible
care.
Additionally, laws are being enacted in many states to ensure
doctors better identify patients with the highest potential risk of
addiction prior to prescribing certain pain medications. In 2017,
Nevada passed ordinance AB 474, which requires all practitioners
prescribing schedule II, III or IV controlled substances to
“(conduct) an evaluation and risk assessment… assessing the mental
health and risk of abuse, dependency and addiction of the patient
using methods supported by peer-reviewed scientific research and
validated by a nationally recognized organization.” Under this new
law, doctors are also required to administer additional addiction
risk assessments every 90 days for patients requiring extended
treatment. Priska™ provides an easy-to-use, cloud-based solution to
address these requirements.
About Priska™
Priska™ is designed to provide assessment data associated
with a patient’s risk for opioid abuse, as well as other mental
health conditions. The Opioid Risk Tool assessment consists of a
5-question survey and fits each patient into one of three risk
categories: low risk, moderate risk or high risk. The peer-reviewed
tool is highly trusted and widely used. Priska brings the
peer-reviewed and nationally-recognized work of Dr. Lynn Webster
into the easily accessible SaaS-based solution. The assessment
gives doctors the insights necessary to ease the burdens associated
in complying with the emerging legal framework in and around pain
management. Webster LR. Predicting aberrant behaviors in
opioid-treated patients: Preliminary validation of the opioid risk
tool. Pain Medicine. 20005;6(6):432-442. Used With Permission.
Disclaimer
Screening is used to identify the likelihood a patient is at
risk of having a specific health condition. However, it does not
provide a diagnosis and should not be used in lieu of or absent
counsel from a medical professional. Priska™ does not function to
deliver a complete and full diagnosis of a patient’s mental health
or any other condition. Priska is designed to be one part of an
overall practitioner’s assessment toolkit, and requires review and
consideration by an accredited practitioner. Pendrake does not and
cannot guarantee, warrant, or certify that use of the Priska
platform and assessments accurately indicate a patient’s risk or
mental condition, or the veracity of a patient’s responses. Priska™
Tools should be used as an ancillary item to help further inform
practitioners who write pain management protocols. Doctors should
however use every tool available to them, such as abuse-deterrent
opioids, lock boxes, safer packaging, government-run prescription
monitoring programs that identify people accessing multiple
prescribers, and state-of-the-art drug tests.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171213005585/en/
For PriskaBrooke Brumfield,
530-414-6259brooke@brookebrumfield.com